Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
8 evidence topics · 8 sources
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings
Not applicable.
Serious hypersensitivity reactions: program-level incidence
“Resolved quickly upon discontinuation of study drug” (opens the source at this quote in a new tab)
“Overall program incidence of ~2%” (opens the source at this quote in a new tab)
Known allergy to ersodetug: exclusion criterion in the tumor hyperinsulinism trial
Hyperglycemia and hepatic safety monitoring: congenital hyperinsulinism program
Safety in tumor hyperinsulinism under expanded access
“Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No hyperglycemia-related adverse events or need for insulin were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote